英文播客:政策银行的贪腐,艾伯维起诉制药新星

阳歌 & 温卫楠
China Development Bank has become the target of the latest anti-corruption crackdown by China’s main graft buster. Will this affect China’s policy of lending big money to developing countries, and if so, what’s driving such a shift?
And AbbVie has filed a suit in the U.S. against BeiGene, one of China’s most up-and-coming young drug makers. What’s likely to happen next in this tug of war between the two companies’ similar blood cancer drugs? Exactly how expensive and destructive are such lawsuits to the companies involved?
国开行成为反腐调查的目标,中国向发展中国家大量投放贷款的政策是否会因此调整?这背后的驱动力到底是什么?
艾伯维在美国向百济神州发起诉讼,后者是中国创新药行业的佼佼者之一。这场白血病药物专利大战会走向何方?类似的官司到底会烧多少钱,产生多少破坏?
关于 China Inc
China Inc是咏竹坊制作的一档播客节目。主要讨论中概股的最新动态,帮助投资者了解这些公司以及它们所处的大环境,并根据相关信息做出正确的决策。
海外用户可以在这些平台上找到我们的播客: